Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640861 · ClinicalTrials.gov registry record · Early Phase 1
Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 45
- Enrollment target
NCT00640861: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT00640861 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 45 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00640861, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is most effective in treating breast cancer. PURPOSE: This randomized clinical trial is studying the side effects of three different vaccine therapies and comparing the vaccines to see how well they work in treating patients with previously treated stage II or stage III breast cancer.
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL HER-2/neu peptide vaccine
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL CpG oligodeoxynucleotide
- BIOLOGICAL MUC-1 peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2008-08-28 |
| Est. Completion | 2015-04-21 |
| Phase | Early Phase 1 |
What the finished NCT00640861 record still lists
NCT00640861 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 5 interventions - of which sargramostim is the first listed.
NCT00640861 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00640861 about?
NCT00640861 is a clinical study titled "Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer". RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is most effective in treating breast cancer. PURPOSE: This randomized clinical trial is studying the side effects of three different vaccine therapies a...
What is the current status of trial NCT00640861?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 45 participants. The study started on 2008-08-28. Estimated completion is 2015-04-21.
What interventions are being tested in trial NCT00640861?
The interventions under investigation include: sargramostim (BIOLOGICAL), HER-2/neu peptide vaccine (BIOLOGICAL), incomplete Freund's adjuvant (BIOLOGICAL), CpG oligodeoxynucleotide (BIOLOGICAL), MUC-1 peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00640861?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00640861's enrollment target sits among peer trials
45 575th of 2000 higher than 1,413 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI